Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Progress on trade talks will determine how far market will move above new highs.Trader Talk with Bob Pisaniread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Palantir Technologies is targeting a valuation of at least $26 billion in a private fundraising round, the first for the Peter Thiel-backed data analytics startup in four...Wall Streetread more
Michael Pack, a conservative filmmaker linked to Steve Bannon, saw at least $1.6 million in donations from his nonprofit sent into the coffers of his independent production...Politicsread more
The New England Patriots released Antonio Brown just 11 days after signing the wide receiver. The NFL Super Bowl champion team initially had kept him in the face of a rape...Sportsread more
The Wall Street Journal's report came as a top Ukraine official said President Donald Trump "is looking" for Ukraine officials to investigate business dealings of Biden's son...Politicsread more
A tour bus carrying Chinese-speaking tourists crashed near a national park in southern Utah, killing at least four people and critically injuring up to 15 others, authorities...U.S. Newsread more
Gun maker Colt announced Thursday that it will halt its production of AR-15 rifles for civilian sales, but the news might not be as exciting for gun control advocates as it...Guns and Weaponsread more
As thousands of people across the world participate in the Global Climate Strike, several Democratic presidential candidates have shared how they will take aggressive action...Scienceread more
Cramer had advocated long positions in these stocks for quite some time. But no more.
"After having some incredible runs this year, I think it's time to ring the register on pretty much any biotech that's smaller than $10 billion," Cramer said.
"The same goes for all of the other small-cap biotechs that are up huge for the year," Cramer said.
Considering the gains, Cramer thinks it would be irresponsible not to take at least some money off the table. In this sector, he feels it's especially prudent given smaller biotechs are often nothing more than bets on FDA approval.
That was the case with Ariad, said Cramer. "Earlier this week, the FDA halted enrollment in clinical trials of Ariad's main drug candidate because it seemed to be causing blood clots. As a result, Ariad lost 66% of its value in a single day."
Now that's not to say Cramer thinks something similar will happen with the stocks listed above – he doesn't. It's not to say he's bearish on the group – he's not.
Read more from Mad Money with Jim Cramer
Cramer: Is this the next big thing?
Cramer's worst case scenario survival guide
Did you miss this bullish tell?
It's simply that biotechs under $10 billion tend to be binary bets on FDA approval. And considering the ytd gains, he thinks it's time to take profits and call it a day.
"I still adore these small-cap biotech companies," Cramer added," but I hate greed, and if you don't ring the register on their stocks here, you are being a bad little piggy."
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the "Mad Money" website? firstname.lastname@example.org